依达拉奉联合尿激酶治疗急性脑梗死的临床疗效观察  

Clinical Observation on Acute Cerebral Infarction Treated with Edaravone and Urokinase

作　　者：周业旺[1] 

机构地区：[1]广西灵山县人民医院神经内科一病区,535400

出　　处：《实用心脑肺血管病杂志》2012年第6期986-987,共2页Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease

摘　　要：目的观察依达拉奉联合尿激酶治疗急性脑梗死的疗效及其安全性。方法将120例急性脑梗死患者随机分为治疗组和对照组各60例,治疗组应用依达拉奉联合尿激酶治疗,对照组单用尿激酶,于治疗前及治疗后7、14d对患者进行神经功能缺损评分,治疗14d进行疗效比较。结果治疗后7、14d治疗组神经功能缺损与对照组比较,差异有统计学意义(P<0.05),治疗14d治疗组疗效明显优于对照组,治疗组总有效率为91.7%,对照组总有效率为81.7%,两组比较差异有统计学意义(P<0.05)。结论依达拉奉联合尿激酶治疗急性脑梗死疗效确切、安全。Objective Observe the efficacy and safety on acute cerebral infarction treated with edaravone and urokinase.Methods 120 cases of acute cerebral infarction patients were randomly divided into the treatment group and control group each 60 cases,the treatment group treated with edaravone and urokinase,and the control group treated with urokinase alone,before and after treatment 7 days and 14 days did neurologic deficits score,14 days comparative efficacy of treatment.Results 7 and 14 days after tratment in treatment group and control group neurologic deficits are statistically significant difference（P0.05）,treatment 14days curative effect of treatment group was better than control group,the total effective rate of the treatment group and control group the total effective rate was 91.7% and 81.7%,two groups of comparisons difference was statistically significant（P0.05）.Conclusion The effect on acute cerebral infarction treated with edaravone and urokinase were definite and safe.

关 键 词：依达拉奉 尿激酶 脑梗死 

分 类 号：R743.33[医药卫生—神经病学与精神病学]